drugset
drugset / Trial / NCT01748877

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

NCT01748877 ↗

Phase 2 Completed 188 enrolled NeurAxon Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is effective in reducing pain levels in patients with post-herpetic neuralgia.

Timeline

Start
2013-01
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject NXN-462 Unknown 200 mg Oral

Indications

postherpetic neuralgia